Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.

Next Previous
Trial Profile

Assessment of Safety and Immunogenicity of Intradermal Electroporation of tetwtCEA DNA in Patients With Colorectal Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carcinoembryonic antigen DNA vaccine (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor; Granulocyte macrophage colony stimulating factor
  • Indications Colorectal cancer
  • Focus Pharmacodynamics
  • Acronyms El-porCEA

Most Recent Events

  • 18 Aug 2022 Status changed from active, no longer recruiting to completed.
  • 27 Feb 2012 Planned End Date changed from 1 Jun 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
  • 27 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top